Cell Therapy - Field Clinical Advisor
About the job
- A bachelor's degree in a health-related field is required; an advanced degree (PharmD, PhD, MSc, NP/PA, MD/RN) is preferred.
- Strong prior experience in clinical research or field-facing roles within oncology/hematology or advanced therapies is required; direct cell therapy experience is strongly preferred.
- Working knowledge of Good Clinical Practice (GCP), clinical trial operations, and the cell therapy patient journey is required.
- Stakeholder management, presentation, and training skills are required, including the ability to translate complex protocols into practical site actions.
- Willingness to travel regionally, nationally, and internationally to support sites and program needs is required.
- A patient- and site-centric mindset with a bias for action and problem solving is required.
- A data-informed approach to identifying trends, risks, and opportunities for operational improvement is required.
- Agility to support multiple studies and indications in a dynamic portfolio environment is required.
- Build and continuously maintain deep knowledge across cell therapy indications and assets, and shape guidance, training, and best practices that raise execution quality and consistency.
- Lead clear, compliant communications conveying strategy, portfolio breadth, and product differentiation; align messaging across regions for assigned protocols and sites.
- Support and deliver site initiation content and advanced protocol education, and implement competency-based training to improve readiness, shorten start-up timelines, and improve protocol adherence.
- Translate inclusion and exclusion criteria and patient flow into practical site actions that raise enrolment rates, reduce screen failures, and minimize attrition.
- Capture and synthesize field insights on feasibility, bottlenecks, and patient pathways; support protocol and process adjustments and drive preventive actions to reduce deviations and data queries.
- Co-create and implement local initiatives with trialists and key experts, track outcomes, and scale successful approaches in line with program priorities.
- Facilitate timely, high-quality scientific dialogues with investigators and internal partners, capture learnings, and ensure governance compliance.
- Coordinate with Clinical Operations, Clinical Development, Medical Affairs, Supply and Logistics, Patient Operations, and Country teams to provide rapid, reliable service to study sites.
- Maintain current knowledge of local regulations, guidelines, and internal policies, and translate requirements into site actions that support inspection readiness.
- Attend relevant scientific meetings and synthesize and share insights; build ecosystem relationships to identify, pilot, and scale innovations that shorten cycle times, improve quality, and enhance site experience.
- Provide country-specific field insights to priority initiatives and shape strategies and deliverables for scalable, locally compliant adoption.
- Partner with Medical Affairs on scientific plans and field content, and coordinate within governance to reflect market dynamics, maintain traceability from field signals to decisions, and operate within policies and standard operating procedures.
- Prior ownership of site performance metrics.
- Prior account leadership and existing relationships in C-suite settings.
- Proven ability to lead trainings, influence without authority, translate complex protocols into practical site actions, escalate concisely, and align stakeholders.
- Prior large-pharma experience in cell therapy.
- Scientific training and/or protocol training expertise.
About the company
AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Get referred to AstraZeneca
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 29 2026 Summit investment adds 12% ownership and fresh ADC combination shots.
- Orpathys plus Tagrisso filed with FDA on October 5 2026 for MET-overexpressing EGFR lung cancer.
- July 2026 Tagrisso victory reduces one major royalty overhang and protects blockbuster economics.
What critics are saying
- Tagrisso and Lynparza face recurring patent fights; July 2026 Federal Circuit only cleared one.
- Summit's ivonescimab remains unproven in US Phase III; FDA decision looms November 14, 2026.
- Pipeline concentration in oncology creates existential risk if ADC combinations disappoint after $2 billion invested.
What makes AstraZeneca unique
- AstraZeneca leads ADC oncology; September 2026 Summit deal extends that franchise.
- Cambridge partnership, October 1 2026, strengthens real-world data and translational evidence generation.
- Wuxi expansion and global footprint support rapid development, launch, and supply execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 9%AstraZeneca signs agreement with Cambridge University Health Partners on using real-world data for better healthcare Published: 05:45, 01 October 2026 More Stories
AstraZeneca places a $2B bet on a Summit Therapeutics cancer drug. AstraZeneca's equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment. By Frank Vinluan on September 29, 2026 3:25 pm AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, a business deal that also kicks off a research collaboration that could pursue multiple drug combinations with an initial focus on gastrointestinal cancers. The deal announced after Monday's market close is a vote of confidence in the Summit cancer drug ivonescimab, a bispecific antibody designed to bind to two targets, PD-1 on T cells and VEGF on cancer cells. Several oncology-focused pharmaceutical companies have already struck deals to add such drugs to their pipelines. Summit's late-clinical drug gives AstraZeneca access to a contender in the class. Ivonescimab was developed by China-based Akeso Therapeutics. Phase 3 trial results in lung cancer raised hopes for the molecule as data showed it beat Merck's blockbuster PD-1 inhibitor Keytruda in a head-to-head study. But those results were from a trial in China, where the drug has approvals in lung cancers and is marketed by Akeso. For Summit, ivonescimab's prospects ride on the results of clinical trials the company is conducting in outside of China. Summit holds rights to the drug in North and South America, Europe, the Middle East, Africa, and Japan. We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey. AstraZeneca is a leader in the development and commercialization of antibody drug conjugates (ADCs) for cancer. The Summit deal gives AstraZeneca the opportunity to test its experimental ADC sonesitatug vedotin (sone-ve) in combination with ivonescimab. In July, AstraZeneca reported sone-ve led to statistically significant improvement in overall survival, meeting the main goal of a Phase 3 test in CLDN18.2-positive gastric cancers. Detailed trial results are scheduled for presentation at the upcoming European Society for Medical Oncology conference in late October. This medical meeting will also include the presentation of data for ivonescimab in biliary tract cancer. Last month, Summit reported preliminary Phase 3 results showing statistically significant improvement. This pivotal study was conducted by Akeso in China. Drug resistance is one limitation of ADCs, but PD-1/VEGF bispecific antibodies may be able to help. In addition to bringing two distinct approaches to cancer, the dual mechanism also makes the tumor microenvironment more favorable to ADCs, which is hoped to overcome resistance. The potential advantages of combining PD-(L)1/VEGF bispecific antibodies with an ADC has led to a flurry of dealmaking to explore such drug pairings. AbbVie, Bristol Myers Squibb, Merck, Pfizer, and have struck business deals for bispecific antibodies in this class. Biotech companies are also striking deals. Late last year, Crescent Biopharma licensed a Kelun Biopharma ADC it plans to test in combination with its PD-1/VEGF bispecific antibody. AstraZeneca's new collaboration could extend beyond sone-ve. The Summit deal includes a non-binding memorandum of understanding that permits additional clinical trials testing ivonescimab in combination with other AstraZeneca cancer drugs, including other ADCs. presented by We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. "A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumor types with combinations alongside next-generation immunotherapies," Susan Galbraith, AstraZeneca executive vice president, oncology hematology R&D, said in a prepared statement. AstraZeneca's Summit investment lends additional validation to the class of bispecific PD-(L)1/VEGF antibodies, Leerink Partners analyst Daina Graybosch said in a research note. But she also characterized the deal as "more tepid than an outright acquisition," adding that while the collaboration may lead AstraZeneca to invest more in Summit, it's also possible the pharma company learns from the trials and then licenses a competing drug in the class. That strategy has precedent. Graybosch pointed to a TROP2-targeting ADC that Merck licensed from Kelun. The deal happened after Merck reviewed data from clinical trials it conducted in collaboration with AstraZeneca and Gilead Sciences. Astrazeneca's agreement with Summit calls for the pharma company to buy about 108,955 shares of its new partner for $18.36 each, representing an 18.6% premium over Monday's closing stock price. The companies will jointly contribute to the costs of the planned clinical trials, which they expect will be sponsored by AstraZeneca. Each company also retains development and commercialization rights to its respective molecules. The deal is expected to close by the end of this week.
AstraZeneca seeks US approval for lung cancer combination. The pharmaceutical company AstraZeneca has submitted an application to the FDA for approval of Orpathys in combination with Tagrisso for locally advanced or metastatic EGFR-mutated lung cancer with MET overexpression or amplification after prior EGFR-directed treatment. Today 11:15 This is stated in a press release from the partner Hutchmed. The application is supported by the phase 3 study SAFFRON, in which the combination improved both progression-free and overall survival compared with platinum-based doublet chemotherapy. Orpathys (with the active substance savolitinib) is being developed jointly through a global collaboration between AstraZeneca and Hutchmed. AstraZeneca 1,677.50 SEK +1.64% (+27.0 SEK)
AstraZeneca has announced a $2 billion equity investment in Summit Therapeutics to advance cancer treatment combinations. The investment will give AstraZeneca approximately 12% of Summit's outstanding common stock. The companies have entered a clinical collaboration to evaluate sonesitatug vedotin, a Claudin-18.2 antibody drug conjugate, combined with ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in gastrointestinal cancers. Trials are set to begin imminently. Each company will retain development and commercial rights to their respective medicines whilst jointly contributing to trial costs. The collaboration aims to broaden AstraZeneca's ADC portfolio across multiple tumour types. AstraZeneca recently reported positive results from the CLARITY-Gastric01 trial for sonesitatug vedotin in advanced gastric cancers, with results to be presented at a 2026 medical congress.
Summit Therapeutics Inc. and astrazeneca enter into clinical trial collaboration to evaluate ivonescimab in combination with sonesitatug vedotin in multiple gastrointestinal cancers. Published on 09/28/2026 at 05:30 pm EDT S&P Capital IQ Summit Therapeutics Inc. entered into a clinical collaboration agreement with AstraZeneca to evaluate sonesitatug vedotin in combination with ivonescimab with the intent to start studies in certain gastrointestinal (GI) cancer settings imminently. Under the terms of the clinical collaboration agreement, each company will contribute their respective compound for the combination studies to be conducted, and the parties will jointly contribute to the costs of such studies, which are intended to be sponsored by AstraZeneca. Each company will retain development and commercial rights to their respective molecules. Moreover, Summit and AstraZeneca intend to evaluate ivonescimab with an additional set of AstraZeneca?s cancer medicines, including other antibody drug conjugates (ADCs). The companies intend to share clinical development costs of potential future studies. Each company will retain their current development and commercial rights to their respective molecules, and the agreement is mutually non-exclusive. There are no additional financial considerations associated with milestones, royalties, revenue-sharing, or profit-sharing. The Memorandum of Understanding with respect to the potential clinical trial collaboration between Summit and AstraZeneca is non-binding, and there can be no assurances that the intended clinical trial collaboration comes to fruition. (C) S&P Capital IQ - 2026